Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community

被引:85
作者
Gerber, Yariv
McConnell, Joseph P.
Jaffe, Allan S.
Weston, Susan A.
Killian, Jill M.
Roger, Veronique L.
机构
[1] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Coll Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Coll Med, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Coll Med, Rochester, MN 55905 USA
关键词
lipoprotein-associated phospholipase A(2); inflammation; risk stratification; secondary prevention; myocardial infarction;
D O I
10.1161/01.ATV.0000240406.89440.0c
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - We evaluated the role of lipoprotein-associated phospholipase A(2) ( Lp- PLA(2)), an inflammatory biomarker, in defining risk after myocardial infarction ( MI). Methods and Results - Olmsted County, Minn, residents who experienced an MI meeting standardized criteria between 2003 and 2005 ( n = 271) were prospectively identified and followed. Lp- PLA2 levels were measured at baseline and evaluated along with traditional risk indicators. Lp- PLA2 was modestly associated with total and low-density lipoprotein cholesterol, smoking, and age ( inversely) but not with MI characteristics or severity, comorbidities, C- reactive protein, or the time from symptom onset to blood sampling. During the first year of follow- up, 42 deaths occurred. The survival estimates ( 95% confidence intervals [ CI]) at 1 year were 92% ( 86% to 98%), 85% ( 78% to 93%), and 74% ( 65% to 84%) in the lowest, middle, and upper Lp- PLA(2) tertiles, respectively ( P = 0.007). After adjustment for age and sex, the hazard ratios for death in the middle and upper Lp- PLA(2) tertiles were 2.20 ( 95% CI: 0.88 to 5.54) and 4.93 ( 95% CI: 2.10 to 11.60), compared with the lowest tertile, respectively ( P-trend < 0.001). Further adjustment for other risk indicators resulted in even stronger associations. Lp- PLA(2) also contributed to risk discrimination as indicated by the increases in the area under the receiver operating characteristic curves obtained in each of the models examined ( all P <= 0.05). Conclusions - Among community subjects presenting with MI, increased Lp- PLA(2) levels measured early after MI are strongly and independently associated with mortality and provide incremental value in risk discrimination over traditional predictors.
引用
收藏
页码:2517 / 2522
页数:6
相关论文
共 46 条
[1]   The effect of statin therapy on lipoprotein associated phospholipase A2 levels [J].
Albert, MA ;
Glynn, RJ ;
Wolfert, RL ;
Ridker, PM .
ATHEROSCLEROSIS, 2005, 182 (01) :193-198
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[3]   European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials [J].
Apple, FS ;
Wu, AHB ;
Jaffe, AS .
AMERICAN HEART JOURNAL, 2002, 144 (06) :981-986
[4]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, P ;
Folsom, AR ;
Chambless, LE ;
Myerson, M ;
Wu, KK ;
Sharrett, AR ;
Boerwinkle, E .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (21) :2479-2484
[5]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[6]   CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease - Application to Clinical and Public Health Practice - Clinical use of inflammatory markers in patients with cardiovascular diseases - A background paper [J].
Biasucci, LM .
CIRCULATION, 2004, 110 (25) :E560-E567
[7]   The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2 [J].
Blackie, JA ;
Bloomer, JC ;
Brown, MJB ;
Cheng, HY ;
Hammond, B ;
Hickey, DMB ;
Ife, RJ ;
Leach, CA ;
Lewis, VA ;
Macphee, CH ;
Milliner, KJ ;
Moores, KE ;
Pinto, IL ;
Smith, SA ;
Stansfield, IG ;
Stanway, SJ ;
Taylor, MA ;
Theobald, CJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (06) :1067-1070
[8]   The discoverv of SB-435495:: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man [J].
Blackie, JA ;
Bloomer, JC ;
Brown, MJB ;
Cheng, HY ;
Elliott, RL ;
Hammond, B ;
Hickey, DMB ;
Ife, RJ ;
Leach, CA ;
Lewis, VA ;
Macphee, CH ;
Milliner, KJ ;
Moores, KE ;
Pinto, IL ;
Smith, SA ;
Stansfield, IG ;
Stanway, SJ ;
Taylor, MA ;
Theobald, CJ ;
Whittaker, CM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) :2603-2606
[9]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[10]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144